Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia
OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive c...
Gespeichert in:
Veröffentlicht in: | Psychiatric services (Washington, D.C.) D.C.), 2001-11, Vol.52 (11), p.1510-1514 |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1514 |
---|---|
container_issue | 11 |
container_start_page | 1510 |
container_title | Psychiatric services (Washington, D.C.) |
container_volume | 52 |
creator | Citrome, Leslie Volavka, Jan Czobor, Pal Sheitman, Brian Lindenmayer, Jean-Pierre McEvoy, Joseph Cooper, Thomas B. Chakos, Miranda Lieberman, Jeffrey A. |
description | OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent. |
doi_str_mv | 10.1176/appi.ps.52.11.1510 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72240211</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72240211</sourcerecordid><originalsourceid>FETCH-LOGICAL-a369t-ef103f56f9703d5166c7d262aad117ee1f1592f4cf0436cdec4a410f8e50f4d63</originalsourceid><addsrcrecordid>eNp9kM1OGzEUha2qqNC0L8Ci8qasmODr8U-yRBGQSkhB0KpLy_XYxGjGdu3JAp4eT5OKHSvfY333XJ2D0CmQOYAUFzolP09lzmnVc-BAPqAT4Fw2S0nIxzoTyRsqW3KMPpfyRAgBCeITOgYQCybZ4gQNV85ZMxYcHV718UUnH-w53vQ6_J_vfUk2-y5OQocOr3Uf9z89jgGvYxl978dnfDnE8Ijv9OhtqJa__bjFD2brX2LaZhu8_oKOnO6L_Xp4Z-jX9dXP1bq53dz8WF3eNroVy7GxDkjruHA1R9txEMLIjgqqdVeDWwsO-JI6ZhxhrTCdNUwzIG5hOXGsE-0Mne19U45_d7aMavDF2L6msnFXlKSUEQpQQboHTY6lZOtUyn7Q-VkBUVPJaipZpaI4rVpNJdelbwf33Z_Bdm8rh1Yr8P0A6GJ077IOxpc3jpElE3wyuthz_448xV0OtZX3Tr8CQi-XJg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72240211</pqid></control><display><type>article</type><title>Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia</title><source>MEDLINE</source><source>American Psychiatric Publishing Journals (1997-Present)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Psychiatry Legacy Collection Online Journals 1844-1996</source><creator>Citrome, Leslie ; Volavka, Jan ; Czobor, Pal ; Sheitman, Brian ; Lindenmayer, Jean-Pierre ; McEvoy, Joseph ; Cooper, Thomas B. ; Chakos, Miranda ; Lieberman, Jeffrey A.</creator><creatorcontrib>Citrome, Leslie ; Volavka, Jan ; Czobor, Pal ; Sheitman, Brian ; Lindenmayer, Jean-Pierre ; McEvoy, Joseph ; Cooper, Thomas B. ; Chakos, Miranda ; Lieberman, Jeffrey A.</creatorcontrib><description>OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent.</description><identifier>ISSN: 1075-2730</identifier><identifier>EISSN: 1557-9700</identifier><identifier>DOI: 10.1176/appi.ps.52.11.1510</identifier><identifier>PMID: 11684748</identifier><language>eng</language><publisher>Washington, DC: American Psychiatric Publishing</publisher><subject>Adult ; Adult and adolescent clinical studies ; Antipsychotic Agents - pharmacology ; Antipsychotic Agents - therapeutic use ; Benzodiazepines ; Biological and medical sciences ; Clozapine - pharmacology ; Clozapine - therapeutic use ; Dose-Response Relationship, Drug ; Double-Blind Method ; Emotions - drug effects ; Female ; Haloperidol - pharmacology ; Haloperidol - therapeutic use ; Hostility ; Humans ; Linear Models ; Male ; Medical sciences ; Neuropharmacology ; Pharmacology. Drug treatments ; Pirenzepine - analogs & derivatives ; Pirenzepine - pharmacology ; Pirenzepine - therapeutic use ; Prospective Studies ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopathology. Psychiatry ; Psychopharmacology ; Psychoses ; Psychotic Disorders - drug therapy ; Psychotic Disorders - psychology ; Risperidone - pharmacology ; Risperidone - therapeutic use ; Schizophrenia ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; Statistics, Nonparametric ; Survival Analysis</subject><ispartof>Psychiatric services (Washington, D.C.), 2001-11, Vol.52 (11), p.1510-1514</ispartof><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a369t-ef103f56f9703d5166c7d262aad117ee1f1592f4cf0436cdec4a410f8e50f4d63</citedby><cites>FETCH-LOGICAL-a369t-ef103f56f9703d5166c7d262aad117ee1f1592f4cf0436cdec4a410f8e50f4d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://psychiatryonline.org/doi/epdf/10.1176/appi.ps.52.11.1510$$EPDF$$P50$$Gappi$$H</linktopdf><linktohtml>$$Uhttps://psychiatryonline.org/doi/full/10.1176/appi.ps.52.11.1510$$EHTML$$P50$$Gappi$$H</linktohtml><link.rule.ids>315,782,786,2859,2863,21635,21636,21637,21638,27933,27934,77801,77802,77804,77809</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=14094650$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11684748$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Citrome, Leslie</creatorcontrib><creatorcontrib>Volavka, Jan</creatorcontrib><creatorcontrib>Czobor, Pal</creatorcontrib><creatorcontrib>Sheitman, Brian</creatorcontrib><creatorcontrib>Lindenmayer, Jean-Pierre</creatorcontrib><creatorcontrib>McEvoy, Joseph</creatorcontrib><creatorcontrib>Cooper, Thomas B.</creatorcontrib><creatorcontrib>Chakos, Miranda</creatorcontrib><creatorcontrib>Lieberman, Jeffrey A.</creatorcontrib><title>Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia</title><title>Psychiatric services (Washington, D.C.)</title><addtitle>Psychiatr Serv</addtitle><description>OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent.</description><subject>Adult</subject><subject>Adult and adolescent clinical studies</subject><subject>Antipsychotic Agents - pharmacology</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Benzodiazepines</subject><subject>Biological and medical sciences</subject><subject>Clozapine - pharmacology</subject><subject>Clozapine - therapeutic use</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Emotions - drug effects</subject><subject>Female</subject><subject>Haloperidol - pharmacology</subject><subject>Haloperidol - therapeutic use</subject><subject>Hostility</subject><subject>Humans</subject><subject>Linear Models</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><subject>Pirenzepine - analogs & derivatives</subject><subject>Pirenzepine - pharmacology</subject><subject>Pirenzepine - therapeutic use</subject><subject>Prospective Studies</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopathology. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Psychoses</subject><subject>Psychotic Disorders - drug therapy</subject><subject>Psychotic Disorders - psychology</subject><subject>Risperidone - pharmacology</subject><subject>Risperidone - therapeutic use</subject><subject>Schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>Statistics, Nonparametric</subject><subject>Survival Analysis</subject><issn>1075-2730</issn><issn>1557-9700</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kM1OGzEUha2qqNC0L8Ci8qasmODr8U-yRBGQSkhB0KpLy_XYxGjGdu3JAp4eT5OKHSvfY333XJ2D0CmQOYAUFzolP09lzmnVc-BAPqAT4Fw2S0nIxzoTyRsqW3KMPpfyRAgBCeITOgYQCybZ4gQNV85ZMxYcHV718UUnH-w53vQ6_J_vfUk2-y5OQocOr3Uf9z89jgGvYxl978dnfDnE8Ijv9OhtqJa__bjFD2brX2LaZhu8_oKOnO6L_Xp4Z-jX9dXP1bq53dz8WF3eNroVy7GxDkjruHA1R9txEMLIjgqqdVeDWwsO-JI6ZhxhrTCdNUwzIG5hOXGsE-0Mne19U45_d7aMavDF2L6msnFXlKSUEQpQQboHTY6lZOtUyn7Q-VkBUVPJaipZpaI4rVpNJdelbwf33Z_Bdm8rh1Yr8P0A6GJ077IOxpc3jpElE3wyuthz_448xV0OtZX3Tr8CQi-XJg</recordid><startdate>20011101</startdate><enddate>20011101</enddate><creator>Citrome, Leslie</creator><creator>Volavka, Jan</creator><creator>Czobor, Pal</creator><creator>Sheitman, Brian</creator><creator>Lindenmayer, Jean-Pierre</creator><creator>McEvoy, Joseph</creator><creator>Cooper, Thomas B.</creator><creator>Chakos, Miranda</creator><creator>Lieberman, Jeffrey A.</creator><general>American Psychiatric Publishing</general><general>American Psychiatric Association</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20011101</creationdate><title>Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia</title><author>Citrome, Leslie ; Volavka, Jan ; Czobor, Pal ; Sheitman, Brian ; Lindenmayer, Jean-Pierre ; McEvoy, Joseph ; Cooper, Thomas B. ; Chakos, Miranda ; Lieberman, Jeffrey A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a369t-ef103f56f9703d5166c7d262aad117ee1f1592f4cf0436cdec4a410f8e50f4d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Adult</topic><topic>Adult and adolescent clinical studies</topic><topic>Antipsychotic Agents - pharmacology</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Benzodiazepines</topic><topic>Biological and medical sciences</topic><topic>Clozapine - pharmacology</topic><topic>Clozapine - therapeutic use</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Emotions - drug effects</topic><topic>Female</topic><topic>Haloperidol - pharmacology</topic><topic>Haloperidol - therapeutic use</topic><topic>Hostility</topic><topic>Humans</topic><topic>Linear Models</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><topic>Pirenzepine - analogs & derivatives</topic><topic>Pirenzepine - pharmacology</topic><topic>Pirenzepine - therapeutic use</topic><topic>Prospective Studies</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopathology. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Psychoses</topic><topic>Psychotic Disorders - drug therapy</topic><topic>Psychotic Disorders - psychology</topic><topic>Risperidone - pharmacology</topic><topic>Risperidone - therapeutic use</topic><topic>Schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>Statistics, Nonparametric</topic><topic>Survival Analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Citrome, Leslie</creatorcontrib><creatorcontrib>Volavka, Jan</creatorcontrib><creatorcontrib>Czobor, Pal</creatorcontrib><creatorcontrib>Sheitman, Brian</creatorcontrib><creatorcontrib>Lindenmayer, Jean-Pierre</creatorcontrib><creatorcontrib>McEvoy, Joseph</creatorcontrib><creatorcontrib>Cooper, Thomas B.</creatorcontrib><creatorcontrib>Chakos, Miranda</creatorcontrib><creatorcontrib>Lieberman, Jeffrey A.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Psychiatric services (Washington, D.C.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Citrome, Leslie</au><au>Volavka, Jan</au><au>Czobor, Pal</au><au>Sheitman, Brian</au><au>Lindenmayer, Jean-Pierre</au><au>McEvoy, Joseph</au><au>Cooper, Thomas B.</au><au>Chakos, Miranda</au><au>Lieberman, Jeffrey A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia</atitle><jtitle>Psychiatric services (Washington, D.C.)</jtitle><addtitle>Psychiatr Serv</addtitle><date>2001-11-01</date><risdate>2001</risdate><volume>52</volume><issue>11</issue><spage>1510</spage><epage>1514</epage><pages>1510-1514</pages><issn>1075-2730</issn><eissn>1557-9700</eissn><abstract>OBJECTIVE: This study compared the specific antiaggressive effects of clozapine with those of olanzapine, risperidone, and haloperidol. METHODS: A total of 157 inpatients with schizophrenia or schizoaffective disorder and a history of suboptimal treatment response were randomly assigned to receive clozapine, olanzapine, risperidone, or haloperidol in a double-blind 14-week trial. The trial was divided into two periods: eight weeks during which the dosage was escalated and then fixed, and six weeks during which variable dosages were used. The hostility item of the Positive and Negative Syndrome Scale (PANSS) was the principal outcome measure. Covariates included the items that reflect positive symptoms of schizophrenia (delusions, suspiciousness or feelings of persecution, grandiosity, unusual thought content, conceptual disorganization, and hallucinations) and the sedation item of the Nurses Observation Scale for Inpatient Evaluation (NOSIE). RESULTS: Patients differed in their treatment response as measured by the hostility item of the PANSS. The scores of patients taking clozapine indicated significantly greater improvement than those of patients taking haloperidol or risperidone. The effect on hostility appeared to be independent of the antipsychotic effect of clozapine on other PANSS items that reflect delusional thinking, a formal thought disorder, or hallucinations and independent of sedation as measured by the NOSIE. Neither risperidone nor olanzapine showed superiority to haloperidol. CONCLUSION: Clozapine has a relative advantage over other antipsychotics as a specific antihostility agent.</abstract><cop>Washington, DC</cop><pub>American Psychiatric Publishing</pub><pmid>11684748</pmid><doi>10.1176/appi.ps.52.11.1510</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1075-2730 |
ispartof | Psychiatric services (Washington, D.C.), 2001-11, Vol.52 (11), p.1510-1514 |
issn | 1075-2730 1557-9700 |
language | eng |
recordid | cdi_proquest_miscellaneous_72240211 |
source | MEDLINE; American Psychiatric Publishing Journals (1997-Present); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Psychiatry Legacy Collection Online Journals 1844-1996 |
subjects | Adult Adult and adolescent clinical studies Antipsychotic Agents - pharmacology Antipsychotic Agents - therapeutic use Benzodiazepines Biological and medical sciences Clozapine - pharmacology Clozapine - therapeutic use Dose-Response Relationship, Drug Double-Blind Method Emotions - drug effects Female Haloperidol - pharmacology Haloperidol - therapeutic use Hostility Humans Linear Models Male Medical sciences Neuropharmacology Pharmacology. Drug treatments Pirenzepine - analogs & derivatives Pirenzepine - pharmacology Pirenzepine - therapeutic use Prospective Studies Psycholeptics: tranquillizer, neuroleptic Psychology. Psychoanalysis. Psychiatry Psychopathology. Psychiatry Psychopharmacology Psychoses Psychotic Disorders - drug therapy Psychotic Disorders - psychology Risperidone - pharmacology Risperidone - therapeutic use Schizophrenia Schizophrenia - drug therapy Schizophrenic Psychology Statistics, Nonparametric Survival Analysis |
title | Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on Hostility Among Patients With Schizophrenia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-02T21%3A39%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Clozapine,%20Olanzapine,%20Risperidone,%20and%20Haloperidol%20on%20Hostility%20Among%20Patients%20With%20Schizophrenia&rft.jtitle=Psychiatric%20services%20(Washington,%20D.C.)&rft.au=Citrome,%20Leslie&rft.date=2001-11-01&rft.volume=52&rft.issue=11&rft.spage=1510&rft.epage=1514&rft.pages=1510-1514&rft.issn=1075-2730&rft.eissn=1557-9700&rft_id=info:doi/10.1176/appi.ps.52.11.1510&rft_dat=%3Cproquest_cross%3E72240211%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72240211&rft_id=info:pmid/11684748&rfr_iscdi=true |